(Q40787456)

23 September 2017

title

Sputum changes associated with therapy for endobronchial exacerbation in cystic fibrosis (English)

1 reference

23 September 2017

0 references

0 references

Smith AL

1

1 reference

23 September 2017

Redding G

2

1 reference

23 September 2017

Doershuk C

3

1 reference

23 September 2017

Goldmann D

4

1 reference

23 September 2017

Gore E

5

1 reference

23 September 2017

Hilman B

6

1 reference

23 September 2017

Marks M

7

1 reference

23 September 2017

Moss R

8

1 reference

23 September 2017

Ramsey B

9

1 reference

23 September 2017

Rubio T

10

1 reference

23 September 2017

language of work or name

English

0 references

publication date

1 April 1988

1 reference

The Journal of Pediatrics

23 September 2017

published in

1 reference

23 September 2017

volume

112

1 reference

23 September 2017

issue

4

1 reference

23 September 2017

page(s)

547-554

1 reference

The pathogenesis and treatment of pulmonary infections in patients with cystic fibrosis

23 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2888%2980165-3

Is anti-Pseudomonas therapy warranted in acute respiratory exacerbations in children with cystic fibrosis?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2888%2980165-3

Tobramycin and ticarcillin therapy for exacerbations of pulmonary disease in patients with cystic fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2888%2980165-3

Treatment of pulmonary infections in patients with cystic fibrosis: A comparative study of ticarcillin and gentamicin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2888%2980165-3

Carbenicillin treatment of Pseudomonas pulmonary infection. Use in children with cystic fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2888%2980165-3

Long-term study of one hundred five patients with cystic fibrosis; studies made over a five- to fourteen-year period

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2888%2980165-3

A new prognostic score and clinical evaluation system for cystic fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2888%2980165-3

Fever of Undetermined Origin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2888%2980165-3

Childhood infections. Diagnostic value of peripheral white blood cell and differential cell counts.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2888%2980165-3

Selective media for the quantitation of bacteria in cystic fibrosis sputum.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2888%2980165-3

A simplification of the protein assay method of Lowry et al. which is more generally applicable

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2888%2980165-3

Pus, deoxyribonucleic acid, and sputum viscosity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2888%2980165-3

New objective criteria for inflammation in bronchial secretions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2888%2980165-3

Granulocyte elastase-alpha 1-antiproteinase complex in cystic fibrosis: sensitive plasma assay for monitoring pulmonary infections.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2888%2980165-3

Sputum examination and the investigation of chronic bronchitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2888%2980165-3

(131-I)ALBUMIN TURNOVER AND LOSS OF PROTEIN INTO THE SPUTUM IN CHRONIC BRONCHITIS

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2888%2980165-3

Bronchial mucus in health and disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2888%2980165-3

Clinical and Bacteriological Responses to Three Antibiotic Regimens for Acute Exacerbations of Cystic Fibrosis: Tlcarcillln-Tobramycin, Azlocillin-Tobramycin, and Azlocillin-Placebo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2888%2980165-3

10.1016/S0022-3476(88)80165-3

7 January 2021

Identifiers

DOI

1 reference

23 September 2017

1 reference